Sund John D, Bollerup Signe, Glamann Jekob B, Vinten Caroline An, Jensen Louise R, Toft-Bethelsen Trine L, Bentzen Bo H, Kledal Thomas N, Weis Nina, Rosenkilde Mette
Infektionsmedicinsk Afdeling, Københavns Universitetshospital - Hvidovre Hospital.
Biomedicinsk Institut, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet.
Ugeskr Laeger. 2022 Jun 13;184(24).
Viroporins are ion channels found in many viruses, where they contribute to virus life cycle and thereby pathogenesis. Viroporin targeting is a known, yet largely unexplored, therapeutic strategy so far only used in Influenza A with the drugs amantadine and rimantadine. In this review, we seek to utilize the inhibition by amantadine of the viroporin Protein E in SARS-CoV-2 in an attempt to treat COVID-19 in its early stages. We are executing a double-blinded placebo-controlled trial based on promising in vivo and in vitro work as a stepping-stone for establishing a therapeutic antiviral regime: blocking of viroporins.
病毒孔蛋白是在许多病毒中发现的离子通道,它们在病毒生命周期中发挥作用,从而导致发病机制。靶向病毒孔蛋白是一种已知但尚未充分探索的治疗策略,迄今为止仅在甲型流感中使用金刚烷胺和金刚乙胺这两种药物。在本综述中,我们试图利用金刚烷胺对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)中病毒孔蛋白E蛋白的抑制作用,来尝试在早期治疗2019冠状病毒病(COVID-19)。基于有前景的体内和体外研究成果,我们正在开展一项双盲安慰剂对照试验,以此作为建立一种治疗性抗病毒方案(即阻断病毒孔蛋白)的垫脚石。